key: cord-0712135-3dconbli
authors: de Melo, Guilherme Dias; Lazarini, Françoise; Levallois, Sylvain; Hautefort, Charlotte; Michel, Vincent; Larrous, Florence; Verillaud, Benjamin; Aparicio, Caroline; Wagner, Sebastien; Gheusi, Gilles; Kergoat, Lauriane; Kornobis, Etienne; Donati, Flora; Cokelaer, Thomas; Hervochon, Rémi; Madec, Yoann; Roze, Emmanuel; Salmon, Dominique; Bourhy, Hervé; Lecuit, Marc; Lledo, Pierre-Marie
title: COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters
date: 2021-05-03
journal: Sci Transl Med
DOI: 10.1126/scitranslmed.abf8396
sha: 925430fdd61f7806e3bba65d21050b4c989498e9
doc_id: 712135
cord_uid: 3dconbli

Whereas recent investigations have revealed viral, inflammatory and vascular factors involved in SARS-CoV-2 lung pathogenesis, the pathophysiology of neurological disorders in COVID-19 remains poorly understood. Olfactory and taste dysfunction are common in COVID-19, especially in mildly symptomatic patients. Here, we conducted a virologic, molecular, and cellular study of the olfactory neuroepithelium of seven patients with COVID-19 presenting with acute loss of smell. We report evidence that the olfactory neuroepithelium may be a major site of SARS-CoV2 infection with multiple cell types, including olfactory sensory neurons, support cells, and immune cells, becoming infected. SARS-CoV-2 replication in the olfactory neuroepithelium was associated with local inflammation. Furthermore, we showed that SARS-CoV-2 induced acute anosmia and ageusia in golden Syrian hamsters, lasting as long as the virus remained in the olfactory epithelium and the olfactory bulb. Finally, olfactory mucosa sampling from patients showing long-term persistence of COVID-19-associated anosmia revealed the presence of virus transcripts and of SARS-CoV-2-infected cells, together with protracted inflammation. SARS-CoV-2 persistence and associated inflammation in the olfactory neuroepithelium may account for prolonged or relapsing symptoms of COVID-19, such as loss of smell, which should be considered for optimal medical management of this disease.

COVID-19, caused by SARS-CoV-2 commonly induces airway and pulmonary symptoms, and in severe cases leads to respiratory distress and death (1) . Although COVID-19 is primarily a respiratory disease, many patients exhibit extra-respiratory symptoms of various severity. Among these, a sudden loss of olfactory function in SARS-CoV-2-infected individuals was reported worldwide at the onset of the pandemic. Loss of smell (anosmia) and/or of taste (ageusia) are considered now as cardinal symptoms of COVID-19 (2) (3) (4) . Likewise, a wide range of central and peripheral neurological manifestations have been observed in severe patients. Although neuropilin-1 was found to facilitate SARS-CoV-2 entry in neural cells (5) , and thus a neurotropism of SARS-CoV-2 could be suspected, a direct role of the virus in the neurological manifestations remains highly debated (2, 6) .

The bona fide virus entry receptor is the angiotensin-converting enzyme 2 (ACE2), which is expressed along the entire CORONAVIRUS COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters human respiratory system, thereby accounting for SARS-CoV-2 respiratory tropism (7, 8) . In the upper airways, and more precisely in the superior-posterior portion of the nasal cavities resides the olfactory mucosa. This region is where the respiratory tract is in direct contact with the central nervous system (CNS), via olfactory sensory neurons (OSN), of which cilia emerge within the nasal cavity and their axons project into the olfactory bulb (9) . As loss of smell is a hallmark of COVID-19, and several respiratory viruses (influenza, endemic human CoVs, SARS-CoV-1) invade the CNS through the olfactory mucosa via a retrograde route (10) , we hypothesized that SARS-CoV-2 might be neurotropic and capable of invading the CNS through OSNs.

SARS-CoV-2 can infect neurons in human brain organoids (11) and recent reports have confirmed the presence of SARS-CoV-2 in olfactory mucosa OSNs that express neuropilin-1 (5) and deeper within the CNS at autopsy (12, 13) . Yet, the portal of entry of SARS-CoV-2 in the CNS remains elusive, as well as the exact mechanism leading to the olfactory dysfunction in COVID-19 patients. Various hypotheses have been proposed such as conductive loss due to obstruction of the olfactory cleft (14) , alteration of OSN neurogenesis (15) and secondary CNS damage related to edema in the olfactory bulb (16, 17) . Detailed study of the olfactory system and olfaction in living patients with COVID-19 is thus needed to investigate the SARS-CoV-2 neuroinvasiveness in the olfactory neuroepithelium.

Complementary to this approach, animal models recapitulating the biological and clinical characteristics of SARS-CoV-2-related anosmia and ageusia would constitute useful tools to address deeper mechanisms. In this regard, wild-type mice are poorly susceptible to SARS-CoV-2 infection as the mouse ACE2 ortholog is not acting as a receptor for this virus (18) , and the various transgenic mouse lines expressing the human version of the virus entry receptor (hACE2) under the control of different promoters, display disproportionate high CNS infection leading to fatal encephalitis (19) (20) (21) (22) , which rarely occurs in patients with COVID-19. This mismatch likely reflects the artefactual ectopic and high expression of hACE2 caused by the different transgene promoters. In contrast, the golden Syrian hamster (Mesocricetus auratus) expresses an endogenous ACE2 protein able to interact with SARS-CoV-2 (18) and constitutes a naturally-permissive model of SARS-CoV-2 infection (23) (24) (25) . Previous reports have shown infection in hamster olfactory mucosa, but whether olfactory neurons can be infected or only non-neuronal, epithelial sustentacular cells, remains controversial (26, 27) . Moreover, the link between infection, inflammation and tissue disruption of the olfactory neuroepithelium and corresponding brain regions is unclear. Likewise, how damage of the neuroepithelium correlates with anosmia, and the potential SARS-CoV-2 neuroinvasion from the olfactory system to its downstream brain structures, remains highly debated.

Here, we report the interactions of SARS-CoV-2 with the olfactory system and its pathophysiological mechanisms. We first investigated SARS-CoV-2 infection of the olfactory mucosa in patients with COVID-19, and recent loss of smell. Because olfactory mucosa biopsy is an invasive procedure, which cannot be used for research purpose in patients with COVID-19, we performed nasal mucosa brush sampling, a non-invasive technique previously used in patients to study neurodegenerative and infectious diseases (28) (29) (30) . We next attempted to model SARS-CoV-2-associated anosmia/ageusia in golden Syrian hamsters to further investigate the pathogenesis of neuroepithelium and CNS infection. Finally, we investigated the olfactory mucosa of post-COVID-19 patients presenting long-lasting olfactory dysfunction.

We enrolled 7 patients that were referred to the ear, nose and throat (ENT) department for olfactory function loss and COVID-19 suspicion in the context of the COVID-19 first wave in Paris, France, alongside with 4 healthy controls. The main clinical features of patients and controls are listed in Tables S1 and S2. The time from first COVID-19-related symptoms to inclusion in the study ranged from 0 to 13 days. None of the patients required hospitalization. Their prominent symptom was recent loss of olfactory function (sudden for 6 patients but progressive for case #1) and was accompanied with taste changes (except case #3) and at least one symptom belonging to the clinical spectrum of COVID-19, such as diarrhea, cough, dyspnea, conjunctivitis, fever, fatigue, headache, muscle pain, laryngitis or a sore throat (Fig. S1A ). Olfactory function loss was the first symptom related to COVID-19 in cases #5 and #14 whereas it was preceded by, or concomitant to other symptoms in the remaining patients. Smell loss was deemed severe for cases #1, #2, #4, #5, #14 and #15, and moderate for case #3. Taste loss was deemed severe for cases #1, #2, #4, #5, and #14 and mild for case #15. The characteristics of the taste and smell abnormalities are listed in Table S3 . Other otolaryngologic symptoms were rhinorrhea for 4 patients, not concomitant with smell loss, nasal irritation for 2 patients and hyperacusis for case #1. Nasal obstruction was not reported in any of the patients. Taste changes were characterized in the 6 patients by dysgeusia where they had a reduced acuity for sweet taste, had a bad taste in the mouth, reduced or increased acuity for bitter, reduced acuity for salt or sour were reported in 4 out of the 6 patients with dysgeusia. Three patients (#2, #4 and #15) were unable to discriminate between different food flavors such as meat and fish.

To investigate whether infection in the olfactory mucosa was associated with olfactory functional loss, all patients (Tables S1  and S2 ). All patients, but none of the controls, had detectable SARS-CoV-2 RNA in cytological samples from the olfactory mucosa using the RT-qPCR SYBR green technique, unambiguously confirming the diagnosis of SARS-CoV-2 infection (Tables S1 and S2). To further investigate if the presence of viral RNA in the olfactory mucosa reflected active replication of SARS-CoV-2 genome, we performed a comparative analysis of genomic and subgenomic copy numbers by RT-qPCR. Patients #2, #14 and #15 exhibited a strong viral genomic RNA load in the olfactory mucosa (2.25. 10 6 RNA copies/μL, 8.09. 10 7 RNA copies/μL, 7.17. 10 6 RNA copies/μL, respectively), and subgenomic RNA was detected in patient #14 (5.66. 10 6 copies/μL), whereas other cases were detected as positive (above the limit of detection with RT-qPCR SYBR green) but not quantifiable (below the limit of quantification, less than 200 RNA copies/μL using the RT-qPCR Taqman technique) (Tables S1 and S2). Given the high viral genomic RNA load in the olfactory mucosa of the patients #14 and #15, we determined the SARS-CoV-2 titer in their olfactory mucosa. Infectious SARS-CoV-2 were isolated from the olfactory mucosa of patients #14 (1.19×10 6 PFU/mL) and #15 (5.38×10 2 PFU/mL) but not in sex-and age-matched controls, indicating that infectious virus is indeed present in the olfactory mucosa of anosmic patients (Table S2) . We further investigated the viral presence in the olfactory mucosa by immunofluorescence labeling of the cytological samples. Variable cell density between olfactory mucosa samples from the COVID-19 and control individuals was found, but all samples contained mature OSNs. Indeed, cells positive for OMP and PGP9.5 were consistently present, and OMP transcripts recovered from all the samples, validating the quality of the swabbing procedure ( Fig. 1A and B; Fig. S1B and Tables S1 and S2). Immunostaining revealed the presence of SARS-CoV-2 antigens (nucleoprotein, NP) in 4 patients (RT-qPCR+) out of 7 but never in controls (Tables S1 and S2, Fig. 1 ). We observed numerous Iba1 + (immune myeloid) cells in the olfactory mucosa of all patients whereas few to no Iba1 + cells in controls ( Fig. 1E and 2A , Tables S1 and S2,). These data suggest that SARS-CoV-2 infection is associated with inflammation of the olfactory mucosa in patients with olfactory impairment, we thus measured the profile of local cytokine and inflammatory mediators. Expression of gene transcript of Cxcl10 was elevated in the olfactory mucosa in most patients with detectable SARS-CoV-2 antigens as compared to control patients, and in contrast, an interindividual variability, both in SARS-CoV-2-infected and control individuals, was observed in Il-6, Ccl5, Isg20 and Mx1 gene transcript expression (Fig. 2D , Tables S1 and S2).

Together, this first set of data indicates that SARS-CoV-2 exhibits an unambiguous tropism for the olfactory neuroepithelium, and this infection is associated with increased local inflammation. We next investigated the identity of the cell types targeted by SARS-CoV-2. We detected SARS-CoV-2infected mature sensory neurons (OMP + ; Fig. 1 , B, C and E, Tables S1 and S2); other SARS-CoV-2 infected cells were sustentacular cells (expressing CK18, Fig. 1D and E, and Fig. S1C ), and myeloid cells (expressing Iba1, Fig. 1E and 2B, Tables S1 and S2). We also detected the presence of immature sensory neurons (Tuj-1 + ) in the olfactory mucosa of all patients, some of them being infected by SARS-CoV-2. Some Iba1 and SARS-CoV-2 positive cells were engulfing portions of Tuj-1 cells in the olfactory mucosa of COVID case #2, suggesting that infected immature sensory neurons were in the process of being phagocytosed by innate immune cells (Fig. 2B ). We next investigated whether infection induces cell death in the olfactory neuroepithelium, by cleaved caspase-3 staining. A strong cleaved caspase-3 signal was detected both in infected and non-infected cells in patients with COVID-19, whereas no signal was detected in samples from control individuals (Fig. 1 , E and F, Fig. 2C , Tables S1 and S2). Altogether these results show that a variety of cell types are infected in the olfactory neuroepithelium of patients with COVID-19, leading to increased cell death through apoptosis. Among them, the loss of mature OSN might be critically relevant in the context of the anosmia. To further assess the impact of neuroepithelium infection by SARS-CoV-2, we infected Syrian golden hamsters to experimentally reproduce anosmia and ageusia, and investigated the potential SARS-CoV-2 infection of the olfactory system and its upstream brain structures.

Syrian golden hamsters (both sexes) were intranasally inoculated with 6.10 4 PFU of SARS-CoV-2 and followed-up between 24h and 14 days post-inoculation (dpi). Clinical, sensorial and behavioral functions were assessed at different timepoints (Fig. S2A ). SARS-CoV-2 inoculation resulted in a decrease in body weight and a degradation in the clinical score as early as 2 dpi, with a peak between 4 and 6 dpi, and sickness resolution by 14 dpi (Fig. 3, A and B) . High viral loads were detected throughout the airways of infected hamsters at 2 and 4 dpi and remained detectable even at 14 dpi (Fig. 3C ) consistent with the well-established respiratory tropism of SARS-CoV-2. In line with our observations in human samples, the nasal turbinates of infected hamsters exhibited high viral loads as soon as 2 dpi. Viral RNA was also detected from 2 dpi and onward in various parts of the brain, including the olfactory bulb, cerebral cortex, brainstem (diencephalon, midbrain, pons and medulla oblongata) and cerebellum (Fig.  3D ). Additionally, we were able to isolate infectious viral particles from the nasal turbinates, the lung and different brain areas (olfactory bulb, cerebral cortex, brainstem and cerebellum), indicative of the replication and production of SARS-CoV-2 in the CNS of hamsters (Fig. 3E ). Having shown the concomitant infection of nasal turbinates and the CNS, we further investigated their impact on sensory and behavioral responses.

We assessed both gustatory and olfactory function of SARS-CoV-2-inoculated hamsters. At 2 dpi, we subjected hamsters to a sucrose preference test. As expected, mock-infected animals displayed a clear preference toward sucrosecomplemented water compared to control water, whereas infected hamsters had no preference toward the sucrose-complemented water (Fig. 4A) , indicative of a SARS-CoV-2associated dysgeusia/ageusia. Moreover, infected animals exhibited signs of hyposmia/anosmia during food findings experiments, as they needed more time to find hidden (buried) food than uninfected hamsters, and a substantial proportion of them (50% at 3dpi and 37.5% at 5 dpi) failed to find the food at the end of the test (Fig. 4 B and C) . Nevertheless, all infected hamsters succeeded to find visible food (Fig. 4C ) revealing that no sickness behavior, visual impairment or locomotor deficit accounted for the delay in finding the hidden food. Also, no locomotor deficit was observed either during the open field ( Fig. S2B ) or painted footprint tests (Fig. S2C ), further excluding a motor deficit bias during the food finding test. At 14 dpi, when weight and clinical score had resumed to normal ( Fig. 3A and B), all hamsters successfully found the hidden food, indicating that infection-associated anosmia recovered spontaneously in this animal model.

We then investigated the impact of SARS-CoV-2 infection on hamster olfactory mucosa, which exhibited high viral loads (Fig. 3C ). The uppermost part of nasal turbinates is overlaid by the olfactory neuroepithelium (Fig. 5A) , a neuroepithelium composed of sensory neurons and support sustentacular cells with both cell populations being ciliated. Imaging by scanning electron microscopy of the olfactory neuroepithelium showed an important loss of ciliation as early as 2 dpi (Fig. 5 B and C, Fig. S3 ) on large portions of the epithelial surface, indicating cilia loss in both OSNs and sustentacular cells. At 4 dpi, viral particles were seen budding from deciliated cells (Fig. 5D ). At 14 dpi, the olfactory mucosa appeared ciliated anew, indistinguishable from that of mockinfected animals ( Fig. 5E and fig. S3 ), consistent with the recovery of olfaction seen in infected hamsters (Fig. 4C ).

In line with the detection of viral particles by electron microscopy at 4 dpi, SARS-CoV-2 was detected in the hamsters' olfactory mucosa at this time point, alongside an infiltration of myeloid Iba1 + cells ( Fig. 6 A-E and J). In the olfactory mucosa, SARS-CoV-2 antigens were found in the cytoplasm of mature (OMP + ; Fig. 6A , B and J) and immature (Tuj1 + ; Fig.  6C , D and J) sensory neurons and in sustentacular cells (CK18 + ; Fig. S4A and B). Some Iba1 + immune cells seen infiltrating the neuroepithelium were positive for SARS-CoV-2, consistent with a potential secondary infection resulting from the phagocytosis of infected cells (Fig. 6D , arrow and Fig. 6J ). Of note, the areas of neuroepithelium containing infected cells were disorganized (see Fig. 6B and D, and Fig.  S4B ), whereas adjacent areas without SARS-CoV-2 remained morphologically intact (Fig. S4C) . Cilia of OMP + neurons located at the apical part of olfactory epithelium were lost in the disorganized infected neuroepithelium (Fig. 4B) . As observed in human samples (see Fig. 2C ), infection induced cell death, with many neuronal and non-neuronal cells being positive for cleaved-caspase-3 in the olfactory mucosa of infected hamsters at 4 dpi (Fig. 6J, Fig. S4D ). Importantly, we observed the expression of cleaved caspase-3 in infected as well as uninfected cells (Fig. S4D , indicating that cell death is not only caused by cytopathic effects of SARS-CoV-2, but also probably by the local inflammation and immune responses to infection.

Having shown that SARS-CoV-2 infects OSNs, and that SARS-CoV-2-infected hamsters exhibit signs of anosmia and ageusia, we wondered whether SARS-CoV-2 invades the CNS via a retrograde route from the olfactory system. SARS-CoV-2 was detected in olfactory nerve bundles close to the neuroepithelium, as demonstrated by the co-localization of SARS-CoV-2 nucleoprotein antigen and OMP + sensory neuron axons reaching the olfactory bulb (Fig. 6E , K and L), consistent with a retrograde infection of axons. Furthermore, SARS-CoV-2 nucleoprotein was detected at the junction of the olfactory nerve and olfactory bulb, seemingly infecting cells of neuronal/glial morphology (Fig. 6F ). In the olfactory bulb, SARS-CoV-2 nucleoprotein was detected in Iba1 + cells ( Fig. 6H ) and in uncharacterized cells ( Fig. 6I and L) in the glomerular layer of the olfactory bulb. The viral nucleoprotein was not detected in other areas of the brain. The high viral RNA loads in the nasal turbinates and in the olfactory bulb, together with the observation of viral antigens along the entire route from the olfactory sensory organ to the bulb, suggests that SARS-CoV-2 enters the brain through the olfactory system, although this finding does not rule out other port of central nervous system entry in patients with COVID-19.

In the nasal turbinates, we detected an intense pro-inflammatory environment, with an up-regulation of Il-6, Cxcl10, Ifn-β, Ifn-λ and Il-1β at 2 dpi, and a slight decrease at 4 and 14 dpi (Fig. 6M) . Similarly, the olfactory bulb exhibited an important up-regulation in the expression of these genes (Fig. 6N ), but in a different and delayed pattern compared to the nasal turbinates: whereas Cxcl10 was overexpressed throughout the infection, there was no change in Ifn-λ, and the increase in Il-6, Ifn-β and Il-1β gene expression was observed only from 4 dpi, with Il-1β remaining up-regulated up to 14 dpi. These data reveal bulbar inflammation during the SARS-CoV-2 infection, possibly in response to signaling via olfactory nerves.

Using RNA-seq, we observed 374 and 51 differentially expressed genes (DEG; increased or decreased, respectively) in the olfactory bulbs of SARS-CoV-2 infected hamsters at 4 dpi (Fig. 7A ). The DEG were classified according to KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways (Fig. 7B ) and the GO (gene ontology) terms based on their biological processes, molecular functions and cellular components (Fig.  7C ). Up-regulated genes were mainly involved in inflammatory responses and responses to virus infection, with innate immunity components (type-I IFN-mediated response, NK cell activation, TLRs, RLRs, NF-κB and Jak-STAT signaling pathways), adaptive immunity components (TH1, T H 2, CD4 + T-cells) and functions related to chemokine signaling. Other biological processes related to nervous system functions were synapse pruning, up-regulation of the neuroinflammatory response, and both astrocyte and microglial activation. To validate the involvement of these signaling pathways, we analyzed the expression of selected targets in the olfactory bulb by RT-qPCR (Fig. 7D) . The genes Mx2, Irf7, Ddx58 and Stat1gene transcripts were found up-regulated early in the infection (2 and 4 dpi), whereas Ccl5 was up-regulated only at 4 dpi. The overexpression of Ccl5 and Irf7 persisted even at 14 dpi. Altogether, SARS-CoV-2-associated inflammation in the bulb confirmed by unbiased RNA-seq analysis, along with the increased viral load detected in the brain parenchyma, supports the assumption that SARS-CoV-2 neuroinvasion drives the neuroinflammation. Of note, Cxcl10, Il-1β, Ccl5 and Irf7 overexpression persisted up to 14 dpi, when animals had recovered from ageusia/anosmia. These data indicate that an infectious or post-infectious inflammatory process persist even in the asymptomatic, or in a delayed post-symptomatic phase, in our animal model.

In some patients, neurological impairments and/or sensory dysfunctions persist several months later from the onset of COVID-19 symptoms, and it has been proposed that this may be linked to persistent viral infection and/or inflammation (31, 32) . We recruited 4 patients with prolonged/recurrent olfactory function loss after COVID-19. The main characteristics of these patients are listed in Table S4 They were recruited between July 15 and 29, 2020, at a time where viral circulation in Paris was very low (<10 cases/100,000 inhabitants/week), implying that SARS-CoV-2 reinfection of these patients was very unlikely. In this case, the time from first COVID-19 related symptoms to inclusion ranged from 110 to 196 days. As a control, we sought to include patients with confirmed COVID-19 but without loss of smell. However, given the relative invasiveness of the olfactory epithelium brushing, the sampling of SARS-CoV-2 infected patients with neither loss of smell nor ENT care was not possible, except for a single individual (47 years old man, recruited in July 2020) presenting long-lasting COVID-19 symptoms (such as dysgeusia, vertigo, paresthesia and tremor, tingling of the face, nose, arms and legs, persisting for >141d), but without any history of anosmia (Table S4) .

The four patients with long-lasting/relapsing loss of smell had been diagnosed with COVID-19 between January and March 2020, based on their initial clinical assessment, including sudden anosmia at disease onset, accompanied with taste changes (except case #8) and at least one clinical sign related to COVID-19, such as fever, fatigue, diarrhea, cough, dyspnea, headache, muscle pain, laryngitis, sore throat, but also paresthesia and vertigo in some patients (Fig. 8A ). Smell loss was complete at disease onset for these patients. Other otolaryngologic symptoms were rhinorrhea for two patients, not concomitant with smell loss and nasal irritation for three patients. Nasal obstruction was reported in patient #10. All had persistent smell loss, persistent taste dysfunction (except case #8) and/or other neurological deficits after COVID-19 at inclusion (Fig. 8A) and were seen at the ENT department for this reason. Neurological signs were stereotypical crises of wriggling nose, left intercostal and non-specific arm pain (case #8), paresthesia (case #9) and vertigo (case #10). The characteristics of taste and smell abnormalities at inclusion are described in Table S5 . Two patients complained of bad taste (Table S2 ). Reduced or increased acuity for bitter, reduced acuity for salt or sour were reported by the two patients with dysgeusia. None of the patients required hospitalization.

These four patients, when consulting with long-lasting/relapsing loss of smell, had no detectable SARS-CoV-2 RNA in nasopharyngeal samples by the mean of routine diagnosis RT-qPCR. However, all of them had detectable SARS-CoV-2 RNA in cytological samples from the olfactory mucosa, using the RT-qPCR SYBR technique (Table S4) . Furthermore, three of them (#8, #9, #10) had a high viral genomic RNA load in the olfactory mucosa (1.68 to 4.35 10 5 RNA copies/μL; Taqman technique), but no subgenomic RNA was detected (Table  S4 ), in favor of a lack of active SARS-CoV-2 replication in the analyzed samples. We further evaluated olfactory mucosa infection by immunofluorescence labeling. We found variable cellularity between olfactory mucosa samples within patients, but all samples contained OSNs, positive for Tuj1, indicating the efficient sampling of the neuroepithelium. Immunostaining revealed the presence of SARS-CoV-2 antigens (N protein) in three out of four patients (Table S4, observed in the samples of all these patients ( Fig. 8D and E, Table S4 ). Quantification of IL-6 gene expression revealed an up-regulation of this proinflammatory cytokine in the olfactory mucosa of the three patients with high viral load, but not in the case #6, which nevertheless presented SARS-CoV-2 antigens in the neuroepithelium (Table S4) . IL-6 expression in the patients with persistent signs of COVID-19 were similar to those of patients with acute COVID-19 (Tables S1-S2, Fig.  8C ). No changes were observed in Ccl5, Cxcl10, Isg20 and Mx1 transcripts (Table S4) . Patient #7, exhibiting long-lasting COVID-19 symptoms but normal sense of smell, had no detectable SARS-CoV-2 RNA in nasopharyngeal samples at inclusion. However, this patient had detectable SARS-CoV-2 RNA in the nasal cytobrush sample using the RT-qPCR SYBR technique and a quantifiable viral genomic RNA load (1.88 10 5 RNA copies/μL; Taqman technique), but neither subgenomic RNA nor SARS-CoV-2 antigen (NP protein) was detected in the olfactory mucosa by immunostaining (Fig. 8D, Table S4 ). Having found that a prolonged carriage of SARS-CoV-2 in the olfactory mucosa is not necessarily associated with loss of smell, we investigated immune responses in the olfactory neuroepithelium of this patient. Although IL-6 expression was high in this patient's sample, very few myeloid cells (Iba1+) were observed and no cell death was detected in harvested cells (Fig. 8E , Table S4).

Altogether, these data indicate that the olfactory neuroepithelium from patients with persistent loss of smell remains infected, with continual SARS-CoV-2 RNA in all of them, and persevering inflammation. Because sustained infection was also found in a patient with long-lasting COVID-19 symptoms and normal sense of smell, but with seemingly less severe inflammation of the olfactory mucosa, we hypothesize that persistence of COVID-19 associated loss of smell is linked to the inflammation caused by persistent infection.

By combining investigations of COVID-19-associated olfactory function loss in patients and experimentally-infected hamsters, both naturally permissive to SARS-CoV-2 infection, we demonstrate that multiple cell types of the olfactory neuroepithelium are infected during the acute phase, at the time when loss of smell manifests, and that protracted viral infection and inflammation in the olfactory neuroepithelium may account for prolonged hyposmia/anosmia.

Olfactory mucosa cytological sampling collected from acute or chronically patients with COVID-19 with olfactory function loss revealed the presence of the SARS-CoV-2 in 100% of patients (n=11) whereas the virus was undetected by RT-qPCR performed at inclusion on conventional nasopharyngeal swabs. Therefore, diagnosing SARS-CoV-2 infection in olfactory mucosa sampled by use of nasal cytobrushes is a more sensitive approach, at least in patients with olfactory function loss, than conventional nasopharyngeal samples. This presence of SARS-CoV-2 RNA and proteins may influence care management of patients with COVID-19 as it may play a role in virus transmission from patients who are thought to be viral-free based on conventional testing, particularly in individuals with mild or no symptoms.

We therefore confirm that SARS-CoV-2 has a tropism for the olfactory mucosa (33) and, most importantly, we demonstrate that it can persist locally, not only a few weeks after general symptoms resolution (34) (35) (36) , but several months in OSNs. Hence, we found that SARS-CoV-2 persists in the olfactory mucosa of patients with prolonged olfactory function loss, up to 6 months after initial diagnosis. Sampling of the olfactory mucosa revealed viral RNA as well as viral antigens, indicating that long-lasting olfactory function loss in these patients correlates with persistence of both viral infection and inflammation, as shown by high expression of inflammatory cytokines including IL-6, and the presence of myeloid cells in cytological samples. Although reinfection by SARS-CoV-2 could not be formally excluded in these patients (31) , the fact that they showed uninterrupted olfactory dysfunction since the onset of the disease, as well as the very low incidence of COVID-19 in France at the time of inclusion, does not support this option. However, there is no absolute correlation between long-term virus carriage and clinical signs, as we also reported here one long COVID-19 case presenting with persistent viral infection without concomitant loss of smell (but with concomitant dysgeusia). The most likely explanation to this observation is the variability of inflammation associated to long-term SARS-CoV-2 carriage, which can be fully asymptomatic (37, 38) or associated with local inflammation and symptoms, such as in the patients who participated in this study. In addition, in the single patient with COVID-19 but without loss of smell, no cell death or immune cells were observed in the olfactory mucosa, but IL-6 was elevated. Therefore, it will be important to formally evaluate the extent of acute inflammation, immune cell infiltration, and cell and tissue damages among larger cohorts of patients with varying degrees of smell loss to extend our observations made on human olfactory mucosa, and to identify the most important determinants of anosmia.

To further study anosmia and the inflammatory process in the olfactory system in the context of COVID-19, we used the golden hamster as an animal model for COVID-19. We show that intranasal SARS-CoV-2 inoculation in hamsters leads to infection of OSNs and induces anosmia, accurately recapitulating what is observed in patients, both clinically and histopathologically. Infection of OSNs in SARS-CoV-2inoculated hamsters has been reported in experiments using similar viral inoculum (26), but not when the inoculum was lower (21) , suggesting a dose-dependent susceptibility of OSNs to infection (5, 27, 39, 40) . Olfactory neurons express Neuropilin-1, a membrane protein involved in SARS-CoV-2 cell entry (5), which may account for olfactory neuron infection. However, they almost do not express SARS-CoV-2 primary receptor ACE2 (41), as opposed to sustentacular cells. Infection of OSNs may happen after infection of adjacent sustentacular cells and horizontally spread of the virus to a neighboring cell. Furthermore, the infiltration of immune cells and the disruption of tissue architecture may contribute to the dissemination of the virus across cells in the olfactory epithelium.

As observed in the tracheal epithelium (42) , infection of the neuroepithelium is associated with cilia loss of the OSNs. Once cilia are restored in the late phase of infection (14 dpi in hamsters), olfaction resumes. Given that odorant receptors accumulate on sensory cilia in the olfactory epithelium, loss of smell in COVID-19 may be explained by the viral-induced cell death of olfactory neurons, or/and also by the disruption of their ciliary structure, preventing the detection of odorant molecules. Although not mutually exclusive, the latter hypothesis would explain why during COVID-19 the onset of anosmia is very sudden, prior to any other respiratory symptoms. Overall, anosmia likely reflects an infection-associated sensorineural dysfunction, that might involve a substantial inflammatory process, neuronal infection, deciliation and cell death, rather than a simple nostril obstruction or tissue edema. The molecular mechanisms underlying neuronal dysfunction remain to be deciphered, but we recently reported that ivermectin strongly reduces loss of smell and is associated to a decrease in inflammation in the nasal turbinates of infected hamsters, without decreasing viral load (43) . Therefore, immune responses induced by olfactory neurons infection might play a role in the onset and persistence of anosmia, and could explain why some infected individuals with SARS-CoV-2 in their nasal cavity never develop anosmia.

We also found that this inflammatory process that takes place in the nasal cavity spreads to the olfactory bulb. This inflammatory transcriptional signature, as shown by RNA Seq and confirmed by qPCR for Il-6, type I IFN (Ifn-β) and Cxcl10 is consistent with the recent neuropathological description of deceased patients with COVID-19, where microgliosis was seen in the olfactory bulb (12) . Importantly, the fact that similar neuropathological alterations are observed in patients with COVID-19 and infected hamsters implies that SARS-CoV-2 infection is likely the cause rather than a consequence of intensive care provided to patients with COVID-19, as previously hypothesized (44) .

Although several viruses are known to invade and disseminate into the brain, whether SARS-CoV-2 does so is highly debated. For instance, viral RNA has been detected in the cerebrospinal fluid and other brain tissues collected from patients who died from COVID-19 (12) , but the neuropathological relevance of these observations remains unclear (6, 13, 45) . The potential SARS-CoV-2 portals of entry to the CNS are (i) retrograde neuroinvasion (via olfactory sensory neurons, glossopharyngeal and/or vagal nerve), (ii) via the blood-brain barrier endothelium (13, 46) and (iii) via peripheral immune cells infiltration (such as T-cells or peripheral macrophages). Although this does not rule out other routes, our study indicates that SARS-CoV-2 indeed does invade the CNS via the retrograde olfactory pathway. Importantly, in addition to the olfactory bulb, viable SARS-CoV-2 was also detected in more remote brain areas of infected hamsters, such as the cerebral cortex and the brainstem, yet without clear visualization of viral antigens. Similarly, viral RNA or protein were observed in the brainstem of patients with COVID-19 (12, 39) , the location of central cardiorespiratory nuclei. Infection of these areas might contribute to the pathogenesis of the respiratory distress reported in patients with COVID-19 and this study therefore constitutes an important step toward elucidating COVID-19-associated putative neurological dysfunctions. Whether neuronal structures are directly targeted by SARS-CoV-2, as opposed to damage by systemic immune responses, is of particular clinical relevance since these two scenarios would require different therapeutic strategies.

Limitations of our study includes the small sample size of the human cohort, especially for patients with COVID-19 without loss of smell. Extending these investigations to a larger group of patients, with varying degree of loss of smell, would allow to precise these first findings. Moreover, this study would benefit from additional approaches to determine the potential dysfunction of brain structures such as the olfactory bulb, by using metabolic PET scan imaging as well as in-depth neurosensory and neurocognitive assessment. Finally, the discovered persistence of SARS-CoV-2 in the olfactory mucosa of patients with long-lasting COVID-19 symptoms requires future validation in larger groups of people from different countries and to set-up new animal models of long COVID.

The persistence of long-lasting COVID-19 symptoms is an important and topical issue as the pandemic continues (47) . This study demonstrates a persistent loss of olfactory function in humans with SARS-CoV-2, for multiple months, lasting as long as the virus remains in the same microenvironment. This might result from direct damage to the OSNs which detect odor in the olfactory epithelium. Further, it provides evidence of SARS-CoV-2 retrograde neuroinvasion via the olfactory route leading to neuroinflammation, and shows the association between viral presence in the olfactory epithelium and anosmia, in both acute (hamsters and humans) and long-lasting in COVID-19 patients. The findings we obtained are clinically relevant in the care to patients with COVID-19, since olfactory function loss could be regarded as a sensitive sign of persistent viral infection, and should be 

The main objective of this study was to investigate SARS-CoV-2 neuroinvasion in humans and the hamster model and to decipher the molecular mechanisms involved. Human olfactory mucosa samples were obtained from a total of 16 living individuals ( APAFIS#25326-2020050617114340 v2.) before experiments were initiated. All animals were randomized to the different experimental groups. Sample sizes were chosen empirically to ensure adequate statistical power. Investigators were not blinded with respect to the origin of the samples. For analysis of the human mucosa, two nasal samples were collected for each participant (one sample per nostril; one immediately frozen and the other one fixed in formalin). Each nasal sample was analyzed three times for SARS-CoV-2 assay by PCR (frozen samples) and immunohistochemistry (formol samples). Nasal samples of two patients and two controls were also titrated for SARS-CoV-2 on cell cultures. In animal experiments, at least four males were used for each time point and replication was performed with the same number of females. Animal samples were analyzed three times for SARS-CoV-2 assay by PCR (frozen samples), immunohistochemistry (formol samples) and titrated by cell cultures (frozen samples). Olfactory mucosa samples of two controls and five SARS-CoV-2 -infected hamsters were analyzed for SARS-CoV-2 by scanning electron microscopy, and 2 control and 3 infected hamsters for immunofluorescence. For microscopy quantification, the value for each animal is the average of 4-8 independently quantified fields. All measurements in humans and hamsters were included in our analysis. Primary data are provided in the figures or the Supplementary Materials.

Subjects with recent olfactory function loss consulting in the Lariboisière hospital (Paris, France) in the context of the COVID-19 screening care for a suspected or confirmed SARS-CoV-2 infection were included during spring and summer 2020. We also recruited subjects with long-lasting/recurrent loss of smell after onset of acute COVID-19 symptoms. Those patients were recruited at the Hotel Dieu Hospital clinic dedicated for patients with long-COVID-19. Among these patients, we included a control patient without loss of smell, consulting for long-term dysgeusia, vertigo, paresthesia, evocative of COVID-19-associated neuroinvasion. Acute illness for those patients was always symptomatic and was either certain if virologically documented (at least one positive SARS-CoV-2 RT-PCR result or positive SARS-CoV-2 serology with IgG and/or IgM antibodies), or probable if at least one major criteria: anosmia/ageusia, contact with a PCR conformed case, typical bilateral pneumonia on CT scan, or three minor criteria among: fever, headaches, fatigue, myalgias, cough, chest pain, chest tightness, unexplained tachycardia, diarrhea, chilblains. We also recruited in this study control subjects consulting in the Ear, Nose and Throat department at the Lariboisière hospital (Paris, France) with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent taste and smell function loss.

All the research participants were included at the Lariboisière Hospital, Paris. They received an oral and written information about the research. Informed consent was obtained by the investigator before any intervention related to the research. The Covidsmell study was performed according to the approved protocol. All patients had a detailed standardized clinical and rhinological examination performed by a certified ENT physician. Following measures were performed at inclusion: i) Taste and olfactory function evaluation by a self-questionnaire taste and smell survey (TTS) (48) , and a visual analog scale (VAS) (49) , and ii) Nasal brushing for collection of neuroepithelium cells and olfactory mucus. The participants self-assessed their smell and taste perception using a 100-mm VAS, where 0 mm indicated the inability to smell or taste and 100 mm indicated normal smell or taste perception (49) .

A certified ENT physician sampled olfactory mucosa of each participant by nasal brushing with safety precautions and after local xylocaine application (Lidocaine 5%) following the method previously described (30) . Briefly, sampling was performed with a sterile 3.5 mm endocervical brush (02.104, Gyneas, Goussainville, France) inserted and gently rolled five times around the inside of both nostrils (360°). Swabs (one per nostril) were placed on ice immediately following collection, and frozen at -80°C or put in formalin solution 10% neutral buffered (HT-5011-1CS, Sigma).

The strain 2019-nCoV/IDF0372/2020 (EVAg collection, Ref-SKU: 014V-03890) was provided by Sylvie Van der Werf, Institut Pasteur, Paris. Viral stocks were produced on Vero-E6 cells infected at a multiplicity of infection of 1.10 −4 PFU (plaque-forming units). The virus was harvested 3 days postinfection, clarified and then aliquoted before storage at -80°C. Viral stocks were titrated on Vero-E6 cells by classical plaque assay using semisolid overlays (Avicel, RC581-NFDR080I, DuPont) (50) .

Male and female Syrian hamsters (Mesocricetus auratus) of 5-6 weeks of age (average weight 60-80 g) were purchased from Janvier Laboratories and handled under specific pathogen-free conditions. Hamsters were housed by groups of 4 animals in isolators in a Biosafety level-3 facility, with ad libitum access to water and food. Before any manipulation, animals underwent an acclimation period of one week. Animal infection was performed as previously described with few modifications (23) . Briefly, the animals were anesthetized with an intraperitoneal injection of 200 mg/kg ketamine (Imalgène 1000, Merial) and 10 mg/kg xylazine (Rompun, Bayer), and 100 μL of physiological solution containing 6.10 4 PFU (plaque-forming units) of SARS-CoV-2 (strain 2019-nCoV/IDF0372/2020, from Pr Sylvie van der Werf) was administered intranasally to each animal (50 μL/nostril). Mockinfected animals received the physiological solution only. Infected and mock-infected animals were housed in separated isolators and all hamsters were followed-up daily when the body weight and the clinical score were noted. The clinical score was based on a cumulative 0-4 scale: ruffled fur, slow movements, apathy, stress when manipulated. At predefined time-points post-infection, animals were submitted to behavioral tests or euthanized, when samples of nasal turbinates, trachea, lungs and the brain (separated in olfactory bulbs, cerebellum, cortex and brainstem) were collected, immediately frozen at -80°C or formalin-fixed after transcardial perfusion with a physiological solution containing 5.10 3 U/mL heparin (choay, Sanofi) followed by 4% neutral buffered formaldehyde.

All behavioral assessment was performed in isolators in a Biosafety level-3 facility that we specially equipped for that.

Sucrose preference test. We measured taste in hamsters by a sucrose preference test based on a two-bottle choice paradigm which paired 2% sucrose with regular water (51) . A reduction in the sucrose preference ratio in experimental infected relative to mock animal is indicative of taste abnormalities. After 6 hours water deprivation, we conducted an individual overnight testing which corresponds to a natural activity period of the hamster. The preference was calculated using the following formula: preference = sucrose intake/total intake × 100%. The total intake value is the sum of the sucrose intake value and the regular water intake Buried food finding test. To assess olfaction, we used the buried food finding test as previously described (52) with few modifications. Hamsters were used only once for each test. Four days before testing, Hamsters received chocolate cereals (Coco pops, Kellogg's) that they ate within one hour. Twenty hours before testing, hamsters were fasted and then individually placed into a fresh cage (37 × 29 × 18 cm) with clean standard bedding for 20 min. Hamsters were placed in another similar cage for 2 min when about 10-12 pieces of cereals were hidden in 1.5 cm bedding in a corner of the test cage. The tested hamster was then placed in the opposite corner and the latency to find the food (defined as the time to locate cereals and start digging) was recorded using a chronometer. The test was carried out during a 15 min period. As soon as food was uncovered, hamsters were removed from the cage. One minute later, hamsters performed the same test but with visible chocolate cereals, positioned upon the bedding.

For scanning electron microscopy, following animal transcardial perfusion in PBS then 4% neutral buffered formaldehyde, hamster whole heads and lungs where fixed in formalin solution 10% neutral buffered (HT-5011-1CS, Sigma), for one week at 4°C to allow neutralization of the virus. Lung and olfactory epithelium small samples were then finely dissected and post-fixed by incubation in 2.5% glutaraldehyde in 0.1 M cacodylate buffer for 1 hour at room temperature then 12 hours at 4°C. The samples were washed in 0.1 M cacodylate then several times in water and processed by alternating incubations in 1% osmium tetroxide and 0.1 M thiocarbohydrazide (OTOTO method), as previously described (53) . After dehydration by incubation in increasing concentrations of ethanol, samples were critical point dried, mounted on a stub, and analyzed by field emission scanning electron microscopy with a Jeol JSM6700F operating at 3 kV.

Tissues from PFA-perfused animals were post-fixed one week in PFA 4%, and olfactory brushes from patients were kept in PFA until further use. After post-fixation, hamster whole heads (without skin and lower jaw) were decalcified in TBD-2 (6764003, ThermoFisher) for 3-5 days, then sagitally cut in half and rinsed in PBS. Organs or brushes were then washed in PBS and dehydrated in 30% sucrose. They were then embedded in O.C.T compound (4583, Tissue-Tek), frozen on dry ice and cryostat-sectioned into 20 μm-thick (hamster organs) or 14 μm-thick (brushes) sections. Sections were rinsed in PBS, and epitope retrieval was performed by incubating sections for 20min in citrate buffer pH 6.0 (C-9999, Sigma-Aldrich) at 96°C for 20min, or overnight at 60°C for whole head sections as they are prone to detaching from the slides. Sections were then blocked in PBS supplemented with 10% goat serum, 4% fetal calf serum and 0.4% Triton X-100 for 2h at room temperature, followed by overnight incubation at 4°C with primary antibodies: rat anti-CD11b ( 

Frozen cytobrushes samples were incubated with Trizol (15596026, Invitrogen) during 5 min and the total RNA was extracted using the Direct-zol RNAMicroPrep Kit (R2062, Zymo Research). The presence of the SARS-CoV-2 in these samples was evaluated by one-step qRT-PCR in a final volume of 25 μL per reaction in 96-well PCR plates using a thermocycler (7500t Real-time PCR system, Applied Biosystems, Applied Biosystems). Briefly, 5 μL of diluted RNA (1:10) was added to 20μL of Superscript III Platinum One-Step qRT-PCR mix (Invitrogen 11746-100) containing 12.5 μL reaction mix, 0.4 μL 50 mM MgSO4, 1.0 μL superscript RT and 6.1 μL of nuclease-free water containing the nCoV_IP2 primers targeting the RdRp gene (nCoV_IP2-12669Fw: 5′-ATGAGCTTAGTCCTGTTG-3′; nCoV_IP2-12759Rv: 5′-CTCCCTTTGTTGTGTTGT-3′) at a final concentration of 1 μM (54) . The amplification conditions were as follows: 1 cycle of 55°C for 20 min, 1 cycle of 95°C for 3 min, 50 cycles of 95°C for 15 s and 58°C for 30 s, 1 cycle of 40°C for 30 s; followed by a melt curve, from 60 °C to 95 °C. The viral load quantification in these samples was assessed using a Taqman one-step qRT-PCR (Invitrogen 11732-020), with the same nCoV_IP2 primers and the nCoV_IP2 probe (5′-FAM-AGATGTCTTGTGCTGCCGGTA-3′-TAMRA) at a final concentration of 1 μM (54) .

The detection of genomic and subgenomic SARS-CoV-2 RNA was based on the E gene (54) using a Taqman one-step qRT-PCR (Invitrogen 11732-020): to detect the genomic RNA we used the E_sarbeco primers and probe (E_Sarbeco_F1 5′-ACAGGTACGTTAATAGTTAATAGCGT-3′; E_Sarbeco_R2 5′-ATATTGCAGCAGTACGCACACA-3′; E_Sarbeco_Probe FAM-5′-ACACTAGCCATCCTTACTGCGCTTCG-3′-TAMRA). The detection of subgenomic SARS-CoV-2 RNA was achieved by replacing the E_Sarbeco_F1 primer by the CoV2sgLead primer (CoV2sgLead-Fw 5′-CGATCTCTTGTAGATCTGTTCTC-3′). A synthetic gene encoding the PCR target sequences was ordered from Thermo Fisher Scientific. A PCR product was amplified using Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific) and in vitro transcribed by means of Ribomax T7 kit (Promega). RNA was quantified using Qubit RNA HS Assay kit (Thermo Fisher scientific), normalized and used as a positive control to quantify RNA absolute copy number.

Total RNA from human cytobrushes was also reverse transcribed to first strand cDNA using the SuperScript IV VILO Master Mix (11766050, Invitrogen). To quantify host inflammatory mediators' transcripts (IL-6, CXCL10, CCL5, Mx1 and ISG20), qPCR was performed in a final volume of 10 μL per reaction in 384-well PCR plates using a thermocycler (QuantStudio 6 Flex, Applied Biosystems). Briefly, 2.5 μL of cDNA (12.5 ng) was added to 7.5 μL of a master mix containing 5 μL of Power SYBR green mix (4367659, Applied Biosystems) and 2.5 μL of nuclease-free water containing predesigned primers (#249900, Qiagen; QuantiTect Primer Assays IL-6: QT00083720; CXCL10: QT01003065; CCL5: QT00090083; Mx1: QT00090895; ISG20: QT00225372; OMP: QT00237055; and GAPDH: QT00079247). The amplification conditions were as follows: 95°C for 10 min, 45 cycles of 95°C for 15 s and 60°C for 1 min; followed by a melt curve, from 60 °C to 95 °C. Variations in the gene expression were calculated as the n-fold change in expression in the tissues compared with the tissues of the control #1.

Frozen tissues were homogenized with Trizol (15596026, Invitrogen) in Lysing Matrix D 2 mL tubes (116913100, MP Biomedicals) using the FastPrep-24 system (MP Biomedicals) and the following scheme: homogenization at 6.5 m/s during 60 s, and centrifugation at 12.000 × g during 2 min at 4°C. The supernatants were collected and the total RNA was then extracted using the Direct-zol RNA MicroPrep Kit (R2062, Zymo Research: olfactory bulb, trachea and nasal turbinates) or MiniPrep Kit (R2052, Zymo Research: lung, brainstem, cerebral cortex and cerebellum) and reverse transcribed to first strand cDNA using the using the SuperScript IV VILO Master Mix (11766050, Invitrogen). qPCR was performed in a final volume of 10 μL per reaction in 384-well PCR plates using a thermocycler (QuantStudio 6 Flex, Applied Biosystems). Briefly, 2.5 μL of cDNA (12.5 ng) was added to 7.5 μL of a master mix containing 5 μL of Power SYBR green mix (4367659, Applied Biosystems) and 2.5 μL of nuclease-free water with the nCoV_IP2 primers (nCoV_IP2-12669Fw: 5′-ATGAGCTTAGTCCTGTTG-3′; nCoV_IP2-12759Rv: 5′-CTCCCTTTGTTGTGTTGT-3′) at a final concentration of 1 μM. The amplification conditions were as follows: 95°C for 10 min, 45 cycles of 95°C for 15 s and 60°C for 1 min; followed by a melt curve, from 60 °C to 95 °C. Viral load quantification in hamster tissues was assessed by linear regression using a standard curve of eight known quantities of plasmids containing the RdRp sequence (ranging from 10 7 to 10° copies). The threshold of detection was established as 200 viral copies/μg of RNA. The Golden hamsters' gene targets were selected for quantifying host inflammatory mediators' transcripts in the tissues using the Hprt (hypoxanthine phosphoribosyltransferase) and the γ-actin genes as reference (Table S6) . Variations in the gene expression were calculated as the n-fold change in expression in the tissues from the infected hamsters compared with the tissues of the uninfected ones using the 2 -ΔΔCt method (55) .

Frozen cytobrushes samples of the patients #14 and #15 and the controls #3 and #4 were incubated with 1 mL of icecold DMEM supplemented with 1% penicillin/streptomycin (15140148, Thermo Fisher) during 5 min. Frozen fragments of hamster tissues (lung, olfactory bulb, brainstem, cerebral cortex, cerebellum) were weighted and homogenized with 1 mL of ice-cold DMEM supplemented with 1% penicillin/streptomycin in Lysing Matrix M 2 mL tubes (116923050-CF, MP Biomedicals) using the FastPrep-24 system (MP Biomedicals) and the following scheme: homogenization at 4.0 m/s during 20 s, incubation at 4°C during 2 min, and new homogenization at 4.0 m/s during 20 s. The tubes were centrifuged at 10.000 × g during 1 min at 4°C. The supernatants were titrated on Vero-E6 cells by classical plaque assays using semisolid overlays (Avicel, RC581-NFDR080I, DuPont) (50) . RNA was isolated from the supernatants using Trizol LS (10296028, Invitrogen) and the Direct-zol RNA MicroPrep Kit (R2062, Zymo Research) as described above.

RNA preparation was used to construct strand specific single end cDNA libraries according to manufacturers' instructions (Truseq Stranded mRNA sample prep kit, Illumina). Illumina NextSeq 500 sequencer was used to sequence libraries. The complete RNA-seq analysis approach is described in the Supplemental information.

Statistical analysis was performed using Stata 16 (StataCorp LLC, Texas, USA) and Prism software (GraphPad, version 8, San Diego, USA), with p < 0.05 considered significant. Quantitative data were compared across groups using Mann-Whitney non-parametric test. Categorical data was compared between groups using Fisher exact test. Associations between the viral load, the olfactory and taste scores, the expression of cytokines, and the time from the first disease symptom were estimated with Spearman non-parametric test. In the animal experiences, time to event were analyzed using Kaplan-Meier estimates and compared across groups using the Logrank test. The degree of markers expression at different dpi were compared to the expression preinfection using Kruskal-Wallis followed by the Dunn's multiple comparison test for unmatched data.

stm.sciencemag.org/cgi/content/full/scitranslmed.abf8396/DC1 Materials and Methods. Fig. S1 . General symptoms and infected cell types in olfactory mucosa of patients with COVID-19 at the acute phase. Table S1 . Features at inclusion of the participants with recent loss of smell associated to COVID-19. Table S2 . SARS-CoV-2 titer in the olfactory mucosa in two patients with recent loss of smell associated to COVID-19. Table S3 . Characteristics of smell and taste abnormalities at inclusion of the participants with recent loss of smell associated to COVID-19. Table S4 . Individual features at inclusion of the participants with persistent olfactory dysfunction. Table S5 . Characteristics of smell and taste abnormalities at inclusion of the participants with persistent olfactory dysfunction. Table S6 . Primer sequences used for qPCR in the golden hamster tissues. Data File S1. Raw data except RNA-seq (provided as supplementary Excel file). Data File S2. Raw data for RNA-seq/ Fig. 7 

Coronavirus Disease (COVID-19) Dashboard

Neurologic Features in Severe SARS-CoV-2 Infection

Olfactory and Gustatory Dysfunction as an Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study

Smell and taste dysfunction in patients with COVID-19

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Anosmia in COVID-19: Mechanisms and Significance

The Olfactory Bulb: An Immunosensory Effector Organ during Neurotropic Viral Infections

SARS-CoV-2 targets neurons of 3D human brain organoids

Neuropathology of patients with COVID-19 in Germany: A post-mortem case series

Multiorgan and Renal Tropism of SARS-CoV-2

Loss of smell in COVID-19 patients: MRI data reveals a transient edema of the olfactory clefts

Anosmia: An evolution of our understanding of its importance in COVID-19 and what questions remain to be answered

Anosmia in COVID-19 Associated with Injury to the Olfactory Bulbs Evident on MRI

Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: Implications for disease pathogenesis and transmissibility

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters

Olfactory epithelium amyloid-beta and paired helical filamenttau pathology in Alzheimer disease

A test for Creutzfeldt-Jakob disease using nasal brushings

stm.sciencemag.org (Page numbers not final at time of first release

HIV-1 detection in the olfactory mucosa of HIV-1-infected participants

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak

Virological assessment of hospitalized patients with COVID-2019

Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19

Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors

Gemelli Against COVID-19 Post-Acute Care Study Group, Persistent Symptoms in Patients After Acute COVID-19

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses

Evolution of antibody immunity to SARS-CoV-2

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

COVID-19 and the Chemical Senses: Supporting Players Take Center Stage

Nonneuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia

SARS-CoV-2 infection damages airway motile cilia and impairs mucociliary clearance. bioRxiv

Anti-COVID-19 efficacy of ivermectin in the golden hamster. bioRxiv

More on Neurologic Features in Severe SARS-CoV-2 Infection

Neuropathological Features of Covid-19

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Long-term consequences of COVID-19: Research needs

Subjective and Objective Assessment of Taste and Smell Sensation in Advanced Cancer

Effects of septorhinoplasty on smell perception

Viral concentration determination through plaque assays: Using traditional and novel overlay systems

Reduction of sucrose preference in the hamster by gymnemic acid

Congenital Cytomegalovirus Infection Alters Olfaction Before Hearing Deterioration In Mice

The dimensions and structural attachments of tip links in mammalian cochlear hair cells and the effects of exposure to different levels of extracellular calcium

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

A new mathematical model for relative quantification in real-time RT-PCR

Icy: An open bioimage informatics platform for extended reproducible research

Tests to assess motor phenotype in mice: A user's guide

Snakemake-A scalable bioinformatics workflow engine

Cutadapt removes adapter sequences from high-throughput sequencing reads

featureCounts: An efficient general purpose program for assigning sequence reads to genomic features

MultiQC: Summarize analysis results for multiple tools and samples in a single report

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

SARTools: A DESeq2-and EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data

PANTHER version 14: More genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools

The GOA database: Gene Ontology annotation updates for 2015

Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool

KEGG: Kyoto encyclopedia of genes and genomes

BioServices: A common Python package to access biological Web Services programmatically

Development of real-time PCR assays for evaluation of immune response and parasite load in golden hamster (Mesocricetus auratus) infected by Leishmania (Viannia) braziliensis

Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)

Differential Innate Immune Responses Elicited by Nipah Virus and Cedar Virus Correlate with Disparate In Vivo Pathogenesis in Hamsters

MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

Acknowledgments: We thank all participants for volunteering for the clinical study.The human sample from which strain 2019-nCoV/IDF0372/2020 was isolated has been provided by X. Lescure